scholarly journals Gut Microbiota Parameters Potentially Useful in Clinical Perspective

2021 ◽  
Vol 9 (11) ◽  
pp. 2402
Author(s):  
Francesco Di Pierro
Keyword(s):  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Fusobacterium Nucleatum ◽  
Routine Practice ◽  
Low Grade ◽  
Clinical Perspective ◽  
Gram Negative ◽  
Colon Neoplasms ◽  
Future Role ◽  
Low Grade Inflammation

Interest in gut microbiota analyses is at an all-time high. Gut microbiota is thought to relate to an increasing range of diseases of interest to physicians and nutritionists. Overweight, obesity, response to diet, metabolic syndrome, low grade inflammation, diabetes and colon neoplasms could maybe be observed in microbiota if affordable markers were available. Possible biomarkers like the Firmicutes/Bacteroidetes ratio, the Gram-positive/Gram-negative ratio, the Prevotella/Bacteroides ratio, and the Fusobacterium nucleatum/Faecalibacterium prausnitzii ratio are here reviewed in a narrative way in the attempt to highlight their possible future role in routine practice and clinically relevant diagnostics.

scholarly journals Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota

2019 ◽  
Vol 317 (6) ◽  
pp. E1121-E1130 ◽  
Author(s):  
Aneseh Adeshirlarijaney ◽  
Jun Zou ◽  
Hao Q. Tran ◽  
Benoit Chassaing ◽  
Andrew T. Gewirtz
Keyword(s):  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Early Stage ◽  
Mechanisms Of Action ◽  
Low Grade ◽  
Inflammatory Agent ◽  
Frontline Treatment ◽  
Anti Inflammatory ◽  
Low Grade Inflammation

Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders. Several mechanisms of action for metformin have been proposed, including that it acts as an anti-inflammatory agent, possibly as a result of its impact on intestinal microbiota. In accord with this possibility, we observed herein that, in mice with diet-induced metabolic syndrome, metformin impacts the gut microbiota by preventing its encroachment upon the host, a feature of metabolic syndrome in mice and humans. However, the ability of metformin to beneficially impact metabolic syndrome in mice was not markedly altered by reduction or elimination of gut microbiota, achieved by the use of antibiotics or germfree mice. Although reducing or eliminating microbiota by itself suppressed diet-induced dysglycemia, other features of metabolic syndrome including obesity, hepatic steatosis, and low-grade inflammation remained suppressed by metformin in the presence or absence of gut microbiota. These results support a role for anti-inflammatory activity of metformin, irrespective of gut microbiota, in driving some of the beneficial impacts of this drug on metabolic syndrome.

Gut Microbiota, Low-grade Inflammation, and Metabolic Syndrome

2013 ◽  
Vol 42 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Benoit Chassaing ◽  
Andrew T. Gewirtz
Keyword(s):  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Low Grade ◽  
Low Grade Inflammation

scholarly journals Resveratrol, Metabolic Syndrome, and Gut Microbiota

Nutrients ◽  
2018 ◽  
Vol 10 (11) ◽  
pp. 1651 ◽  
Author(s):  
Alice Chaplin ◽  
Christian Carpéné ◽  
Josep Mercader
Keyword(s):  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Therapeutic Potential ◽  
Low Grade ◽  
Bacterial Composition ◽  
Beneficial Effects ◽  
Metabolic Outcomes ◽  
Associated Conditions ◽  
Glucose And Lipid Homeostasis ◽  
Low Grade Inflammation

Resveratrol is a polyphenol which has been shown to have beneficial effects on metabolic syndrome-related alterations in experimental animals, including glucose and lipid homeostasis improvement and a reduction in fat mass, blood pressure, low-grade inflammation, and oxidative stress. Clinical trials have been carried out to address its potential; however, results are still inconclusive. Even though resveratrol is partly metabolized by gut microbiota, the relevance of this “forgotten organ” had not been widely considered. However, in the past few years, data has emerged suggesting that the therapeutic potential of this compound may be due to its interaction with gut microbiota, reporting changes in bacterial composition associated with beneficial metabolic outcomes. Even though data is still scarce and for the most part observational, it is promising nevertheless, suggesting that resveratrol supplementation could be a useful tool for the treatment of metabolic syndrome and its associated conditions.

Evidence from comparative genomic analyses indicating that Lactobacillus-mediated irritable bowel syndrome alleviation is mediated by the conjugated linoleic acid synthesis

2021 ◽  
Author(s):  
Yang Liu ◽  
Wei Xiao ◽  
Leilei Yu ◽  
Fengwei Tian ◽  
Gang Wang ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Linoleic Acid ◽  
Gut Microbiota ◽  
Acid Synthesis ◽  
Comparative Genomic ◽  
Low Grade ◽  
Genomic Analyses ◽  
Irritable Bowel ◽  
Low Grade Inflammation ◽  
Gut Microbiota Dysbiosis

Irritable bowel syndrome (IBS) is a chronic intestinal disorder accompanied by low-grade inflammation, visceral hypersensitivity, and gut microbiota dysbiosis. Several studies have indicated that Lactobacillus supplementation can help to alleviate...

Regulation of Metabolism: A Cross Talk Between Gut Microbiota and Its Human Host

Physiology ◽  
2012 ◽  
Vol 27 (5) ◽  
pp. 300-307 ◽  
Author(s):  
Rémy Burcelin
Keyword(s):  
Immune System ◽  
Gut Microbiota ◽  
Low Grade ◽  
Gene Products ◽  
Individual Level ◽  
Obesity And Diabetes ◽  
Regulation Of Metabolism ◽  
Molecular Origin ◽  
The Individual ◽  
Low Grade Inflammation

The recent epidemic of obesity and diabetes and the diversity at the individual level could be explained by the intestinal microbiota-to-host relationship. More than four million gene products from the microbiome could interact with the immune system to induce a tissue metabolic infection, which is the molecular origin of the low-grade inflammation that characterizes the onset of obesity and diabetes.

Modulation of gut microbiota by Mantequilla and Melipona honeys decrease low-grade inflammation caused by high fructose corn syrup or sucrose in rats

2021 ◽  
pp. 110856
Author(s):  
Diana Coutiño-Hernández ◽  
Mónica Sánchez-Tapia ◽  
Francisco Leal-Vega ◽  
Miriam Bobadilla del Valle ◽  
Héctor Ledezma ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Low Grade ◽  
High Fructose Corn Syrup ◽  
Corn Syrup ◽  
High Fructose ◽  
Low Grade Inflammation
Sign in / Sign up

Export Citation Format

Share Document